Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Munch-a-Biotech Today -- Ignore unavailable to you. Want to Upgrade?

To: RCMac who wrote (299)	3/23/1999 8:06:00 PM
From: scaram(o)uche	Read Replies (1) \| Respond to of 3158

MEDI-507..... say it works for both acute GvH and psoriasis.... that would indicate that it might be likely to work for transplantation and autoimmunity in general. That spells huge markets, and the flow-through to BTRN is a "true" double-digit royalty, with MEDI taking care of the inventors separately. So..... one year of royalties, six years after introduction...... let's say $150 million. What do you think BTRN is worth to any company that has confidence in the potential efficacy of 507, when administered on a chronic basis? I'm not saying that MEDI has such confidence.